In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients

Lipids in Health and Disease

Marios-C Lazanas¹  Constantinos A Demopoulos³  Panagiotis Gargalianos²  Smaragdi Antonopoulou⁵  Elizabeth Fragopoulou⁵  Katherina Psarra⁴  Alexandros B Tsoupras³  Nickolaos Tsogas¹  George M Stamatakis³  Nikos Mangafas¹  Maria Chini¹  Vasiliki D Papakonstantinou³ 

[1] 3rd Internal Medicine Department-Infectious Diseases Unit, Red Cross General Hospital, Athens, Greece;1st Internal Medicine Department-Infectious Diseases Unit, “G. Gennimatas” Hospital, Athens, Greece;Faculty of Chemistry, National & Kapodistrian University of Athens, Panepistimioupolis Zografou, 15771 Athens, Greece;Department of Immunology and Histocompatibility, Evangelismos Hospital, Athens, Greece;Department of Science Nutrition-Dietetics, Harokopio University, Athens, Greece

关键词: Efavirenz;    Abacavir;    Tenofovir-DF;    Cardiovascular disease;    Human immunodeficiency virus;    Inflammation;    Cytokines;    Platelet activating factor;   

Others  :  801185
DOI  :  10.1186/1476-511X-13-90

 received in 2014-04-05, accepted in 2014-05-24,  发布年份 2014

【 摘 要 】

Background

Persistent immune activation and inflammation are lying behind HIV-infection even in the setting of ART mediated viral suppression. The purpose of this study is to define the in vivo effect of two first-line ART regimens on certain inflammatory mediators in male HIV patients.

Methods

Male, naive, HIV-infected volunteers were assigned either to tenofovir-DF/emtricitabine/efavirenz (Group_T) or abacavir/lamivudine/efavirenz (Group_A). Platelet Activating Factor (PAF) levels and metabolic enzymes together with HIV-implicated cytokines (IL-1beta, IL-6, IL-8, IL-10, IL-12p70, TNFa) and VEGF were determined for a 12-month period. Differences within each group were determined by non-parametric Friedman and Wilcoxon test, while the differences between the groups were checked by ANOVA repeated measures.

Results

Both ART regimens present pronounced effect on inflammatory mediators, resulting in decreased PAF levels and Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity for tenofovir-containing regimen and same as baseline PAF levels with a peak though at the 3^rd month as well as elevated Lp-PLA2 activity for abacavir-containing regimen.

Conclusions

Studies regarding the effect of first-line ART regimens on inflammation may be beneficial in preventing chronic morbidities during HIV-treatment. From this point of view, the present study suggests an anti-inflammatory effect of tenofovir-containing ART, while the temporary increase of PAF levels in abacavir-containing ART may be the link between the reported cardiovascular risk and abacavir administration.

【 授权许可】

   
2014 Papakonstantinou et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Taiwo B, Barcena L, Tressler R: Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy. Curr HIV/AIDS Rep 2013, 10:21-32.
• [2]Hunt PW: HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep 2012, 9:139-147.
• [3]Plaeger SF, Collins BS, Musib R, Deeks SG, Read S, Embry A: Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary. AIDS Res Hum Retroviruses 2012, 28:469-477.
• [4]Miller CJ, Baker JV, Bormann AM, Erlandson KM, Huppler Hullsiek K, Justice AC, Neuhaus J, Paredes R, Petoumenos K, Wentworth D, Winston A, Wolfson J, Neaton JD, Insight S, Groups ES: Adjudicated Morbidity and Mortality Outcomes by Age among Individuals with HIV Infection on Suppressive Antiretroviral Therapy. PloS one 2014, 9:e95061.
• [5]Venketaraman V, Morris D, Donohou C, Sipin A, Kung S, Oh H, Franklin M, Murad JP, Khasawneh FT, Saviola B, Guilford T, Donahue C: Role of Cytokines and Chemokines in HIV Infection. In HIV and AIDS - Updates on Biology, Immunology, Epidemiology and Treatment Strategies. Edited by Dumais N. Croatia: InTech; 2011:281-300.
• [6]MacLeod IJ, Rowley CF, Lockman S, Ogwu A, Moyo S, van Widenfelt E, Mmalane M, Makhema J, Essex M, Shapiro RL: Abacavir alters the transcription of inflammatory cytokines in virologically suppressed, HIV-infected women. J Int AIDS Soc 2012, 15:17393.
• [7]Lundgren J, Neuhaus J, Babiker A, Cooper D, Duprez D, El-Sadr W, Emery S, Gordin FM, Kowalska J, Phillips A, Prineas R, Reiss P, Sabin CA, Tracy R, Weber R, Grund B, Neaton J: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008, 22:F17-F24.
• [8]Palella FJ Jr, Gange SJ, Benning L, Jacobson L, Kaplan RC, Landay AL, Tracy RP, Elion R: Inflammatory biomarkers and abacavir use in the Women’s Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS 2010, 24:1657-1665.
• [9]Padilla S, Masia M, Garcia N, Jarrin I, Tormo C, Gutierrez F: Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. BMC Infect Dis 2011, 11:40. BioMed Central Full Text
• [10]Kim C, Gupta SK, Green L, Taylor BM, Deuter-Reinhard M, Desta Z, Clauss M: Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells. Antivir Ther 2011, 16:1335-1339.
• [11]Demopoulos CA, Pinckard RN, Hanahan DJ: Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem 1979, 254:9355-9358.
• [12]Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM: The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 2002, 30:S294-S301.
• [13]Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM: Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci 2003, 40:643-672.
• [14]Demopoulos CA, Karantonis HC, Antonopoulou S: Platelet activating factor - a molecular link between atherosclerosis theories. Eur J Lipid Sci Technol 2003, 105:705-716.
• [15]Snyder F: Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes [published errata appear in Biochim Biophys Acta 1995 Aug 3;1257(3):297 and 1995 Oct 26;1259(1):121]. Acta Biochim Biophys 1995, 1254:231-249.
• [16]Snyder F: CDP-choline:alkylacetylglycerol cholinephosphotransferase catalyzes the final step in the de novo synthesis of platelet-activating factor. Bba-Lipid Lipid Met 1997, 1348:111-116.
• [17]Shindou H, Hishikawa D, Nakanishi H, Harayama T, Ishii S, Taguchi R, Shimizu T: A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells. Cloning and characterization of acetyl-CoA:LYSO-PAF acetyltransferase. J Biol Chem 2007, 282:6532-6539.
• [18]Stafforini DM, Prescott SM, McIntyre TM: Human plasma platelet-activating factor acetylhydrolase. Purification and properties. J Biol Chem 1987, 262:4223-4230.
• [19]Genis P, Jett M, Bernton EW, Boyle T, Gelbard HA, Dzenko K, Keane RW, Resnick L, Mizrachi Y, Volsky DJ, Epstein LG, Gendelman HE: Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease. J Exp Med 1992, 176:1703-1718.
• [20]Del Sorbo L, Arese M, Giraudo E, Tizzani M, Biancone L, Bussolino F, Camussi G: Tat-induced platelet-activating factor synthesis contributes to the angiogenic effect of HIV-1 Tat. Eur J Immunol 2001, 31:376-383.
• [21]Biancone L, Cantaluppi V, Boccellino M, Bussolati B, Del Sorbo L, Conaldi PG, Albini A, Toniolo A, Camussi G: Motility induced by human immunodeficiency virus-1 Tat on Kaposi’s sarcoma cells requires platelet-activating factor synthesis. Am J Pathol 1999, 155:1731-1739.
• [22]Perry SW, Hamilton JA, Tjoelker LW, Dbaibo G, Dzenko KA, Epstein LG, Hannun Y, Whittaker JS, Dewhurst S, Gelbard HA: Platelet-activating factor receptor activation. An initiator step in HIV-1 neuropathogenesis. J Biol Chem 1998, 273:17660-17664.
• [23]Arese M, Ferrandi C, Primo L, Camussi G, Bussolino F: HIV-1 Tat protein stimulates in vivo vascular permeability and lymphomononuclear cell recruitment. J Immunol 2001, 166:1380-1388.
• [24]Doublier S, Zennaro C, Spatola T, Lupia E, Bottelli A, Deregibus MC, Carraro M, Conaldi PG, Camussi G: HIV-1 Tat reduces nephrin in human podocytes: a potential mechanism for enhanced glomerular permeability in HIV-associated nephropathy. AIDS 2007, 21:423-432.
• [25]Tsoupras AB, Chini M, Tsogas N, Fragopoulou E, Nomikos T, Lioni A, Mangafas N, Demopoulos CA, Antonopoulou S, Lazanas MC: Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection? Aids Res Human Retroviruses 2008, 24:1079-1086.
• [26]Martin M, Serradji N, Dereuddre-Bosquet N, Le Pavec G, Fichet G, Lamouri A, Heymans F, Godfroid JJ, Clayette P, Dormont D: PMS-601, a new platelet-activating factor receptor antagonist that inhibits human immunodeficiency virus replication and potentiates zidovudine activity in macrophages. Antimicrob Agents Chemother 2000, 44:3150-3154.
• [27]Sallem W, Serradji N, Dereuddre-Bosquet N, Dive G, Clayette P, Heymans F: Structure-activity relationships in platelet-activating factor. Part 14: synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 activity. Bioorg Med Chem 2006, 14:7999-8013.
• [28]Serradji N, Bensaid O, Martin M, Sallem W, Dereuddre-Bosquet N, Benmehdi H, Redeuilh C, Lamouri A, Dive G, Clayette P, Heymans F: Structure-activity relationships in platelet-activating factor. Part 13: synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 or pure antiretroviral activity. Bioorg Med Chem 2006, 14:8109-8125.
• [29]Tsoupras AB, Chini M, Mangafas N, Tsogas N, Stamatakis G, Tsantila N, Fragopoulou E, Antonopoulou S, Gargalianos P, Demopoulos CA, Lazanas MC: Platelet-activating factor and its basic metabolic enzymes in blood of naive HIV-infected patients. Angiology 2012, 63:343-352.
• [30]Khovidhunkit W, Memon RA, Shigenaga JK, Pang M, Schambelan M, Mulligan K, Feingold KR, Grunfeld C: Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Metabolism 1999, 48:1524-1531.
• [31]Eggert D, Dash PK, Serradji N, Dong CZ, Clayette P, Heymans F, Dou H, Gorantla S, Gelbard HA, Poluektova L, Gendelman HE: Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders. J Neuroimmunol 2009, 213:47-59.
• [32]Persidsky Y, Limoges J, Rasmussen J, Zheng J, Gearing A, Gendelman HE: Reduction in glial immunity and neuropathology by a PAF antagonist and an MMP and TNFalpha inhibitor in SCID mice with HIV-1 encephalitis. J Neuroimmunol 2001, 114:57-68.
• [33]Schifitto G, Sacktor N, Marder K, McDermott MP, McArthur JC, Kieburtz K, Small S, Epstein LG: Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium. Neurology 1999, 53:391-396.
• [34]Chini M, Tsoupras AB, Mangafas N, Tsogas N, Papakonstantinou VD, Fragopoulou E, Antonopoulou S, Gargalianos P, Demopoulos CA, Lazanas MC: Effects of HAART on platelet-activating factor metabolism in naive HIV-infected patients I: study of the tenofovir-DF/emtricitabine/efavirenz HAART regimen. AIDS Res Hum Retroviruses 2012, 28:766-775.
• [35]Chini M, Tsoupras AB, Mangafas N, Tsogas N, Papakonstantinou VD, Fragopoulou E, Antonopoulou S, Gargalianos P, Demopoulos CA, Lazanas MC: Effects of highly active antiretroviral therapy on platelet activating factor metabolism in naive HIV-infected patients: ii) study of the abacavir/lamivudine/efavirenz HAART regimen. Int J Immunopathol Pharmacol 2012, 25:247-258.
• [36]Clumeck N, Pozniak A, Raffi F, Committee EE: European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV medicine 2008, 9:65-71.
• [37]Services DoHaH: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2009, 1-161.
• [38]Demopoulos CA, Andrikopoulos NK, Antonopoulou S: A simple and precise method for the routine determination of platelet-activating factor in blood and urine. Lipids 1994, 29:305-309.
• [39]Bligh EG, Dyer WJ: A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959, 37:911-917.
• [40]Kolovou V, Papakonstantinou VD, Stamatakis G, Verouti SN, Xanthopoulou MN, Kolovou G, Demopoulos CA: Platelet activating factor levels and metabolism in tangier disease: a case study. Lipids Health Dis 2012, 11:89. BioMed Central Full Text
• [41]Phillips AN, Neaton J, Lundgren JD: The role of HIV in serious diseases other than AIDS. AIDS 2008, 22:2409-2418.
• [42]Detopoulou P, Nomikos T, Fragopoulou E, Stamatakis G, Panagiotakos DB, Antonopoulou S: PAF and its metabolic enzymes in healthy volunteers: interrelations and correlations with basic characteristics. Prostaglandins Other Lipid Mediat 2012, 97:43-49.
• [43]Packard CJ: Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target. Curr Opin Cardiol 2009, 24:358-363.
• [44]Nowlan ML, Drewe E, Bulsara H, Esposito N, Robins RA, Tighe PJ, Powell RJ, Todd I: Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatology 2006, 45:31-37.
• [45]Bussolino F, Camussi G, Baglioni C: Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1 alpha. J Biol Chem 1988, 263:11856-11861.
• [46]Ruis NM, Rose JK, Valone FH: Tumor necrosis factor release by human monocytes stimulated with platelet-activating factor. Lipids 1991, 26:1060-1064.